PCSK9 inhibition following outcomes data: what now?

Organized with the participation of Amgen

Vendredi 19 Janvier 2018   12:30-13:30   Maillot room
Lunch debate (organized with the participation of Industry)
12:30 • Michel Farnier
PCSK9: an accelerated development story
Denis Angoulvant
12:50 • Denis Angoulvant
Decrease cholesterol further: lower is definitely better
Who would be the priority patients?